Achromobacter is not contagious in the way most people think of contagious infections. It does not spread through casual contact like a cold or the flu. This bacterium lives naturally in water and soil, and the vast majority of infections come from environmental exposure or contaminated medical equipment rather than from another person. The one important exception involves people with cystic fibrosis, where indirect patient-to-patient transmission has been documented.
How Achromobacter Spreads
Achromobacter is a waterborne, environmental bacterium. It thrives in wet environments: sink drains, shower drains, water supplies, mud, and even dental chair water lines. Research sampling hospitals, homes, and outdoor areas found the bacterium in hand-washing sinks, shower drains, kitchen sink drains, and sluice sinks across nearly all settings tested. Interestingly, it has never been recovered from toilet bowls in any study environment.
In hospitals, outbreaks have been traced to contaminated medical supplies rather than person-to-person spread. One well-documented outbreak occurred at a radiology clinic in France, where an aide accidentally contaminated a container used to soak sponges for prostate biopsies. The prolonged reuse of that container allowed the bacteria to multiply, and patients were infected through contact with contaminated equipment during the procedure. Other hospital outbreaks have been linked to contaminated mouthwash, soaps, intravenous fluids, incubators, and ultrasound gel.
For most healthy people, encountering Achromobacter in a sink drain or shower poses no real threat. The bacterium is an opportunistic pathogen, meaning it only causes disease when it finds a way past the body’s normal defenses.
The Cystic Fibrosis Exception
The one situation where person-to-person transmission is a genuine concern involves cystic fibrosis. Achromobacter has become an increasingly recognized pathogen in CF lungs as diagnostic techniques have improved, and cross-infection between CF patients has been confirmed even after brief, indirect contact.
Two well-documented cases illustrate the risk. In one, a young, stable CF patient with normal lung function visited the home of another CF patient who carried Achromobacter ruhlandii. In the second, a CF patient shared vacation facilities with an infected CF patient during a skiing trip. Both previously uninfected patients became colonized with the same strain of Achromobacter in their airways and sinuses, and both experienced clinical deterioration afterward. One went on to develop chronic infection despite aggressive antibiotic treatment.
Because of risks like these, infection control guidelines for CF care recommend that patients maintain a distance of more than three feet from other CF patients at all times, contain their respiratory secretions, and avoid socializing in close quarters. In hospitals, CF patients should not share rooms. These precautions apply broadly to prevent transmission of several dangerous bacteria, not just Achromobacter.
Who Is Actually at Risk
Achromobacter almost exclusively causes illness in people whose immune systems are already compromised. In a study of 14 infection cases at Indian hospitals, every single patient had at least one underlying health condition. Half had diabetes. Nearly 30% had blood cancers, and all of those patients developed infection after starting chemotherapy. Other common risk factors included chronic lung disease, kidney failure, liver cirrhosis, lupus, and treatment with high-dose steroids or other immunosuppressive drugs.
Medical devices create another entry point. Nine of those 14 patients had a central or peripheral intravenous line at the time they developed bloodstream infection, and five required mechanical ventilation. The bacterium takes advantage of these breaks in the body’s barriers.
When Achromobacter does cause infection, it can affect multiple body systems. Bloodstream infections are the most common presentation in immunocompromised patients, but it has also been reported in cases of pneumonia, urinary tract infections, meningitis, and heart valve infections.
Why Achromobacter Infections Are Hard to Treat
Part of what makes this bacterium concerning when it does infect someone is its extensive resistance to antibiotics. Achromobacter carries at least 50 genes associated with drug resistance, including enzymes that break down common antibiotics and 17 different efflux pumps, which are molecular machinery that actively expel antibiotics from the bacterial cell before they can work.
Some strains go further. Researchers have identified “hypermutator” strains that accumulate resistance-boosting mutations at an accelerated rate, making them progressively harder to treat over time. This is especially relevant for CF patients, where the bacterium can persist in the lungs for months or years and evolve within a single patient. One study found that strains isolated later from the same patient had acquired new mutations affecting antibiotic resistance compared to the original infecting strain.
Reducing Your Risk at Home and in Hospitals
Since Achromobacter lives in drains and wet surfaces, people who are immunocompromised or have CF should be aware that household plumbing is a potential reservoir. The bacterium was found in roughly one-third of homes sampled in one study, primarily in shower drains, bathroom sinks, and kitchen sinks. Regular cleaning of drains and avoiding prolonged standing water in sinks can reduce bacterial buildup, though no specific home disinfection protocol has been validated for Achromobacter specifically.
In healthcare settings, the key preventive measures focus on proper handling of medical equipment and supplies. Hospital outbreaks have been stopped by identifying and removing contaminated devices, implementing dual-staff verification for handling certain equipment, and enforcing standard hand hygiene and contact precautions. For CF patients specifically, the most effective strategy remains physical separation from other CF patients, both in clinical settings and in everyday social situations.